Analyses from the FinHER trial revealed that TNBC with higher TILs at diagnosis experienced decreased distant recurrence rates, while HER2+ BC with higher TILs derived increased trastuzumab benefit [95]. This evidence concerns the gene ERBB2 and breast cancer.